StockData
AstraZeneca PLC logo

AstraZeneca PLC (AZN) operating KPIs

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca saphnelo (anifrolumab) — Established RoW YoY actual (%) (%)

Form 6-K / 20-F Product Sales Table

QuarterlyAnnual
Latest, Q2 2026
31.0%
Period ended Jun 30, 2026
Change on a year earlier
-10.0 pts
41.0% in Q2 2025
History
13 quarters
Since Q3 2021
Sources
13
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSaphnelo (anifrolumab) — Established RoW YoY actual (%) (%)Year on yearSource
Q2 2026Jun 30, 202631.0%-10.0 ptsForm 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 202653.0%+2.0 ptsForm 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 202534.0%-41.0 ptsForm 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 202594.0%+57.0 ptsForm 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 202541.0%-49.0 ptsForm 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 202551.0%-29.0 ptsForm 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 202475.0%–Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 202437.0%–Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 202490.0%–Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 202480.0%–Form 6-K FY2024Q1 Earnings Release ↗
Q1 2022Mar 31, 20220.0%–Form 6-K FY2022Q1 Earnings Release ↗
Q4 2021Dec 31, 20210.0%–Form 6-K FY2021Q4 Earnings Release ↗
Q3 2021Sep 30, 20210.0%–Form 6-K FY2021Q3 Earnings Release ↗

Cite this data

StockData. (2026). AstraZeneca Saphnelo (anifrolumab) — Established RoW YoY actual (%) (%), quarterly Q3 2021–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_saphnelo_erow_act_yoy

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.